Advertisement
Advertisement
U.S. markets open in 8 hours 17 minutes
Advertisement
Advertisement
Advertisement
Advertisement

Pluristem Therapeutics Inc. (PSTI)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.5500+0.1800 (+13.14%)
At close: 04:00PM EDT
1.6000 +0.05 (+3.23%)
After hours: 06:01PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Previous Close1.3700
Open1.3700
Bid0.0000 x 800
Ask0.0000 x 800
Day's Range1.3500 - 1.6500
52 Week Range1.3100 - 4.5500
Volume204,921
Avg. Volume175,009
Market Cap50.139M
Beta (5Y Monthly)2.00
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for PSTI

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Pluristem Therapeutics, Inc.
    VCEL: Raising target price to $22.00VERICEL CORP has an Investment Rating of SELL; a target price of $22.000000; an Industry Subrating of High; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
    Rating
    Fair Value
    Economic Moat
    8 days agoArgus Research
View more
  • GlobeNewswire

    Pluristem and Tnuva to Ring Nasdaq Closing Bell in Honor of New Partnership

    Closing Bell Ringing Ceremony Will Take Place on Monday, March 28 at 3:45 pm ET at Nasdaq MarketSite in Times Square, New York A live stream of the Nasdaq Closing Bell will be available at: https://livestream.com/accounts/27896496/events/10177910 HAIFA, Israel, March 28, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI) (“Pluristem”), a leading biotechnology company, and Tnuva Group (“Tnuva Group” or “Tnuva”), Israel’s largest food producer, today announced that Pl

  • GlobeNewswire

    Pluristem Releases PLX-R18 Hematology Phase I Study Results: Data Show Increase in All Blood Lines and Reduction in Blood Transfusions

    Results show the potential in the use of PLX-R18 for meaningful advantage over other existing and proposed treatments in post hematopoietic cell transplantation (HCT) patients.PLX-R18 reduced mortality from 29% to 18%1 and was well-tolerated with a favorable safety profile.PLX-R18 was granted Orphan Drug Designation by the U.S. Food and Drug Administration (FDA) for the treatment of graft failure and incomplete hematopoietic recovery following HCT and the prevention and treatment of acute radiat

  • GlobeNewswire

    Pluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint Venture

    Eyal Rosenthal (photo credit Jim Vetter) Eyal Rosenthal, CEO of Tnuva and Pluristem's new joint venture. Photographed by Jim Vetter. HAIFA, Israel, March 08, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq: PSTI) (TASE: PSTI), a leading biotechnology company (“Pluristem”), and Tnuva Group (“Tnuva Group” or “Tnuva”), Israel’s largest food producer, today jointly announced the appointment of Eyal Rosenthal as Chief Executive Officer of their landmark joint venture to develop, manufact

Advertisement
Advertisement